How Safe Are Biological Agents in Pediatric Rheumatology?
Objective: Biologic therapy has changed the prognosis of patients with rheumatologic disease. Despite all benefits of the biological agents, adverse events may occur due to their long-term use. The aim of this study is to analyze the adverse events observed in pediatric patients who received biologi...
Saved in:
Main Authors: | Emine Nur Sunar Yayla (Author), Çisem Yıldız (Author), Pelin Esmeray Şenol (Author), Nihal Karaçayır (Author), Deniz Gezgin Yıldırım (Author), Sevcan A. Bakkaloğlu (Author) |
---|---|
Format: | Book |
Published: |
AVES Yayincilik,
2024-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
How common is remission in rheumatoid factor-positive juvenile idiopathic arthritis patients? The multicenter Pediatric Rheumatology Academy (PeRA) research group experience
by: Semanur Ozdel, et al.
Published: (2023) -
GISEA: an Italian biological agents registry in rheumatology
by: F. Trotta, et al.
Published: (2011) -
COVID-19 pandemic and biological therapy in rheumatologic disorders: how to deal with?
by: Z. Ahmadinejad, et al.
Published: (2020) -
BIOLOGIC THERAPY IN PEDIATRIC RHEUMATOLOGY
by: A. A. Baranov, et al.
Published: (2011) -
BIOLOGIC THERAPY IN PEDIATRIC RHEUMATOLOGY
by: A. A. Baranov, et al.
Published: (2011)